PERCEVAL Pivotal Trial

• ClinicalTrials.gov Identifier: NCT00860730
• Recruitment Status: Completed
• First Posted: March 12, 2009
• Last Update Posted: January 22, 2019
• Sponsor: LivaNova
• Information provided by (Responsible Party): LivaNova

Study Description

Brief Summary:

The clinical investigation is designed as a prospective and non-randomised study on a maximum of 150 patients. This study will be conducted at Investigational Centres in the European Community. A minimum number of 8 European Centres will be involved in the clinical investigation. A minimum of 15 patients will be enrolled at each Investigational Centre. The clinical follow-up requires evaluations at discharge (or 30 days if the patient is still hospitalized), 3-6 and 12 months following the procedure.The primary objective of this clinical investigation is to assess the performance of the Perceval S valve at 3-6 months after implantation in high surgical risk patients, who require a surgical intervention to replace the aortic valve.

Condition or disease	Intervention/treatment	Phase
Aortic Valve Replacement	Device: Aortic valve replacement with Perceval aortic heart valve	Not Applicable

Detailed Description:

The design of the Perceval S prosthesis stems from the intention to offer an alternative to traditional flexible prostheses (stented and stentless biological valves) using conventional open-heart surgery. As a result of the sutureless implant procedure, in fact, patients could benefit from:

Reducing aortic clamp times, with subsequent overall reduction of surgical timing and therefore reduction in related risks; Avoiding to pass the stitches through the annulus and sutures knotting, with consequent less risk of tearing aortic annulus and wall, damaging the bundle of His, embolizing foreign material in the vascular system.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 150 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: PERCEVAL Pivotal Trial
• Study Start Date: January 2009
• Actual Primary Completion Date: October 2009
• Actual Study Completion Date: October 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Perceval S	Device: Aortic valve replacement with Perceval aortic heart valve; Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis

Outcome Measures

Primary Outcome Measures :

1. Evaluation of the safety of the Perceval S prosthesis in terms of percentage incidence of mortality and morbidity at 3-6 months after implant [ Time Frame: 6 months ]

Secondary Outcome Measures :

1. Assessment of mortality and morbidity rates at discharge (or 30 days if the patient is still hospitalized) and 12 months after implant [ Time Frame: 12 months ]

Eligibility Criteria

• Ages Eligible for Study: 75 Years and older (Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subjects of 75 years or older;
• Subjects with aortic valve stenosis or steno-insufficiency;
• Subjects at high surgical risk and candidates for aortic valve replacement with a biological prosthesis;
• Subjects in NYHA functional classes III and IV with the Logistic EuroSCORE greater than 5%.
• Subjects who have agreed to participation in the clinical evaluation and who have signed the informed consent;
• Subjects who are willing to undergo all the medical follow-ups and echocardiographic examinations and laboratory tests that form part of this present protocol.

Exclusion Criteria:

• Subjects involved in any other clinical study for drugs or devices;
• Subjects who have previously undergone implantation with the Perceval S prosthesis being assessed;
• Subjects with previous implantation of valve prostheses or annuloplasty ring in mitral position;
• Subjects requiring simultaneous procedures, apart from septal myectomy and/or coronary by-pass;
• Subjects with aneurysmal dilation or dissection of the ascending aortic wall needing surgical correction;
• Subjects needing non elective intervention;
• Subjects with aortic annulus (after procedure for decalcification) of dimensions such that the implantation of a valve of size 21 or 23 mm is not possible (direct intra-operative measurement with sizer), in accordance with the indications reported in the Investigator's Brochure;
• Subjects with active endocarditis;
• Subjects with active myocarditis;
• Subjects with any anomaly of the coronary ostia determined through pre-operative coronary angiogram or during intervention itself;
• Subjects with congenital bicuspid aortic valve;
• Subjects with aortic root enlargement, where the ratio between observed and expected diameters (calculated as a function of age and patient body surface area) is > 1.3;
• Subjects with aortic root enlargement, where the ratio between the diameter of the sino-tubular junction and the annulus diameter is > 1.3;
• Subjects with myocardial infarct < =90 days;
• Subjects with known hypersensitivity to nickel alloys.

Contacts and Locations

Locations

Belgium

UZ Leuven

Leuven, Belgium, 3000

France

CHRU de Lille

Lille, France, 59037

Hopital Guillaume et René Laennec

Nantes, France, 44093

Institut Mutualiste Montsouris

Paris, France, 75014

Hôpital Cardiologique du Haut-Lévêque

Pessac, France, 33604

Germany

Ruhr Universität Bochum

Bochum, Germany, 44789

Westdeutsches Herzzentrum

Essen, Germany, 45122

Medizinische Hochschule Hannover

Hannover, Germany, 30625

Switzerland

Inselspital Bern

Bern, Switzerland, 3010

Sponsors and Collaborators

LivaNova

Investigators

• Principal Investigator: Axel Haverich, Prof; Hannover Medizinische Hochschule

More Information

Additional Information:

Website 

• Responsible Party: LivaNova
• ClinicalTrials.gov Identifier: NCT00860730
• Other Study ID Numbers: V10801
• First Posted: March 12, 2009
• Last Update Posted: January 22, 2019
• Last Verified: January 2019

Keywords provided by LivaNova:

Aortic valve replacement; Aortic stenosis; Biological valve; Sutureless valve; Stented valve; Aortic Valve Disease